Last updated: June 15, 2026
CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA (1:19-cv-00956): Litigation Summary, Status, and Patent Exposure Analysis
CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA, No. 1:19-cv-00956, is a US Hatch-Waxman patent infringement case filed in the District of Delaware in 2019. The matter is tied to CyDex’s branded drug portfolio and Alembic’s US generic regulatory pathway, with the litigation posture and ultimate patent-handling outcome governed by the ANDA/Paragraph IV framework and the court’s case-management and scheduling orders.
What follows is the litigation summary and analysis based on the docket identifier you provided (1:19-cv-00956).
What patents were asserted in CyDex Pharmaceuticals v. Alembic Global Holding SA (1:19-cv-00956)?
Direct outcome: No complete asserted-patent list is available from the information provided in the prompt alone.
What is typically asserted in a Hatch-Waxman case like this
In Paragraph IV ANDA litigations in Delaware, the plaintiff typically asserts:
- One or more Orange Book-listed US patents covering the drug substance, formulation, or method of use
- Claims tied to the specific dosage form and label described in the ANDA
- A subset of claims after pleadings, often narrowed through claim construction and later summary judgment
Case-specific asserted patents: Not specified in the provided input.
When was the case filed and what procedural milestones matter (1:19-cv-00956)?
Direct outcome: The filing year (2019) is implied by the docket number year, but exact procedural milestones (complaint filing date, answer date, motions, hearings, and claim construction dates) are not stated in the provided input.
Milestones that drive settlement vs trial in ANDA cases
Even without the dates, the high-value timeline elements for assessing resolution are:
- Complaint filing and service
- ANDA technical and non-infringement contentions from the ANDA filer (Alembic)
- Invalidity contentions and expert discovery scope
- Markman/claim construction schedule
- Summary judgment or stipulated dismissal events
- Consent judgment / covenant-not-to-sue
- Final judgment triggering or preserving generic launch timing
Case-specific milestone dates: Not available from the prompt.
What is the Delaware docket posture: stayed, settled, dismissed, or tried?
Direct outcome: The prompt provides only the case caption and docket number; it does not provide dispositive docket outcomes (dismissal, settlement, or final judgment).
How to interpret posture for exclusivity and entry risk
For business and licensing decisions, the posture determines:
- Whether Alembic was blocked until patent expiry
- Whether entry was enabled by settlement carve-outs, licensed rights, or judgment invalidating asserted claims
- Whether appeal risks remain and whether a final appellate mandate affects remaining enforcement
Case-specific posture: Not specified in the provided input.
How does a Paragraph IV ANDA litigation like 1:19-cv-00956 affect generic launch timing?
Direct outcome: Specific launch timing impact cannot be quantified without:
- the asserted patents and their expiration dates
- whether the court entered a final judgment
- whether a settlement created a launch date or “carve-out” period
Entry mechanics that determine timing
In typical Hatch-Waxman structure:
- Filing of an ANDA with a Paragraph IV certification triggers a statutory 30-month stay unless court decisions end the stay earlier.
- The stay can be shortened if the court finds invalidity or non-infringement, and can be extended by later filings or post-trial events.
- If the case settles, the settlement often sets a negotiated:
- launch date
- design-around conditions
- exclusivity duration
- royalty/licensing terms (sometimes)
- dismissal with prejudice or entry of judgment
Case-specific timing impact: Not computable from the provided input.
Which parties besides CyDex and Alembic typically appear in this type of case (and what does it imply)?
Direct outcome: No additional parties are listed in the prompt.
Common involvement patterns
Depending on the portfolio, related entities may appear as:
- co-plaintiffs owning specific Orange Book patents
- co-defendants tied to manufacturing or ANDA labeling
- brand-law firms or generic counsel reflecting joint defense structures
- interested pharmaceutical manufacturers if contract manufacturing is implicated
Case-specific party list: Not available from the provided input.
What Orange Book status would likely govern this dispute, and what listings matter?
Direct outcome: The prompt does not identify:
- the specific CyDex-branded active ingredient
- the Orange Book patents in play
Orange Book listings that matter in infringement scope
In practice, the litigated Orange Book patents usually fall into:
- Drug substance process or polymorph patents
- Drug product formulation patents (composition, stabilizers, particle size, coatings)
- Method-of-use patents tied to dosing or therapeutic regimen
- Bioavailability or performance patents tied to the ANDA’s submitted BE profile
Case-specific Orange Book mapping: Not available from the provided input.
What is the patent strength profile implied by typical CyDex vs generic disputes?
Direct outcome: No asserted patent set or claim scope is provided, so no strength scoring can be calculated.
Strength metrics typically assessed
Patent strength for Hatch-Waxman cases is assessed by:
- claim breadth for infringement reach
- written description and enablement risk under §112
- prior art density for obviousness
- prosecution history estoppel and claim construction narrowness
- test of commercial reality (does the generic design around actually avoid claim scope?)
Case-specific patent strength: Not computable from the prompt.
What generic entry risks exist for Alembic if CyDex’s asserted claims are limited or dismissed?
Direct outcome: Without:
- asserted patents
- final judgment or dismissal terms
- any licensing or covenant structure
the entry risk cannot be quantified.
Risk categories
For business planning, the key risk buckets are:
- Design-around success risk (whether Alembic’s proposed formulation or method avoids all surviving claims)
- Remaining asserted claim risk (even if some patents fall, others may remain enforceable)
- Appeal pendency risk (whether an appellate stay blocks entry)
- Enforcement risk (post-judgment infringement suits if the generic launches)
Case-specific entry risk: Not computable from the provided input.
Did CyDex and Alembic reach a settlement, and what settlement terms typically cover?
Direct outcome: The prompt does not provide settlement status or terms.
Settlement terms that drive enforceability and market timing
Settlement agreements in these cases usually address:
- scope and duration of permitted sales
- dismissal provisions
- license grants or covenants not to sue
- non-admission clauses
- confidentiality and dispute resolution
- carve-outs for potential future changes to labeling or manufacturing
Case-specific settlement details: Not available from the provided input.
What regulatory status would align with the litigation (FDA ANDA, labeling, and exclusivity)?
Direct outcome: The drug identity is not provided; therefore, FDA pathway details cannot be tied to the litigation.
What to map once the NDA/ANDA is identified
For a complete regulatory risk view, the mapping requires:
- ANDA submission date and application number
- Paragraph IV certification and patent numbers
- tentative approval timeline
- Orange Book expiration and any pediatric exclusivity or orphan exclusivity (if applicable)
- labeling carve-outs from settlement
Case-specific FDA status: Not available from the provided input.
How does the case compare with other CyDex generic challenges against Alembic or similar filers?
Direct outcome: No comparators or case list are provided.
What comparison typically reveals
Cross-case comparison typically identifies:
- repeat asserted patents across multiple generics
- whether CyDex uses broad formulation claims consistently
- whether defendants win on claim construction trends
- whether CyDex settlements cluster around common launch windows
Case-specific comparative analysis: Not computable from the prompt.
Key Takeaways
- The docket identifier CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA, 1:19-cv-00956 identifies a 2019 Hatch-Waxman-style patent infringement dispute in Delaware, but the prompt does not provide the asserted patents, dates of dispositive orders, or final outcome required for a litigation-grade analysis.
- Without the Orange Book patent list and the court outcome, market entry timing, exclusivity impact, and patent strength cannot be quantified.
- Any business decision tied to Alembic’s generic exposure requires the asserted-patent set and the docket’s disposition, neither of which is included in the provided input.
FAQs
- What is the typical legal framework for CyDex-style ANDA Paragraph IV cases in Delaware?
- How do 30-month stays interact with settlement agreements in Hatch-Waxman litigation?
- What claim categories (substance, formulation, method of use) most often determine claim construction outcomes?
- How do appellate timelines affect generic launch if a district court decision is appealed?
- What Orange Book data points most directly control the scope of infringement in ANDA cases?
References (APA)
- CyDex Pharmaceuticals, Inc. v. Alembic Global Holding SA, No. 1:19-cv-00956 (D. Del. 2019).
